Perlecan-Targeted Nanoparticles for Drug Delivery to Triple-Negative Breast Cancer
Future Drug Discovery · 2019
DOI: 10.4155/fdd-2019-0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Drug Discovery, 2019. Verfasst von Vidhi Khanna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIBIB NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Förderung
- NIBIB NIH HHS
- National Institutes of Health
Zitieren
APA
Khanna, V., Kalscheuer, S., Kirtane, A., Zhang, W., & Panyam, J. (2019). Perlecan-Targeted Nanoparticles for Drug Delivery to Triple-Negative Breast Cancer. Future Drug Discovery. https://doi.org/10.4155/fdd-2019-0005
Vancouver
Khanna V, Kalscheuer S, Kirtane A, Zhang W, Panyam J. Perlecan-Targeted Nanoparticles for Drug Delivery to Triple-Negative Breast Cancer. Future Drug Discovery. 2019. doi:10.4155/fdd-2019-0005
BibTeX
@article{Khanna2019,
author = {Khanna, Vidhi and Kalscheuer, Stephen and Kirtane, Ameya and Zhang, Wenqiu and Panyam, Jayanth},
title = {Perlecan-Targeted Nanoparticles for Drug Delivery to Triple-Negative Breast Cancer},
journal = {Future Drug Discovery},
year = {2019},
doi = {10.4155/fdd-2019-0005}
}
EUVIMED